

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

C. Liaw et al.

: Art Unit: 1646

Serial No.:

09/875,076

: Examiner: P. Mertz

Filed:

June 6, 2001

: Confirmation No.: 6379

For:

NUCLEIC ACID ENCODING

HUMAN G PROTEIN-COUPLED

RECEPTOR

Via Express Mail Label No: EV147590461US Date Sent: February 20, 2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants submit herewith several references filed in related, non-priority cases. Applicants' respectfully submit that these references are being submitted contemporaneously with the issue fee. The references are being submitted in view of Applicants' duty of candor although Applicants' believe they are not material to the claimed invention. The references are being submitted only because of the relationship of the applications to one another, although different subject matter is claimed in each. It is our understanding that these references will be placed in the permanent file. A copy of each listed reference is also enclosed.

This submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

03/09/2004 SLUANG1 00000001 501275 09875076

01 FC:1806

180.00 DA

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Please charge the required fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 50-1275.

Respectfully submitted,

Michael A Patané

Registration No. 42,982 Attorney for Applicants

Enclosures:

Form PTO/SB/08B Copy of References Cited

Dated: February 20, 2004

Cozen O'Connor 1900 Market Street – 5th Floor Philadelphia, PA 19103

Tel: 215-665-2000 Fax: 215-665-2013

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FEB 2 0 2004 Substitute for form 1449A/PTO ⊮NFORMATION DISCLOSURE STATEMENT BY APPLICANT

TRACE!

Complete if Known 09/875.076 Application Number Filing Date June 6, 2001 Ruoping Chen First Named Inventor Art Unit 1646 **Examiner Name** Prema Mertz 11.US9.DIV

(use as many sheets as necessary)

Sheet of 2 Attorney Docket Number

	U.S. PATENT DOCUMENTS					
Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevar	
Initials *		Number - Kind Code ² (if known)		Cited Document	Passages or Relevant Figures Appear	
	AA	US-2003/0125539 A1	07/03/2003	Bonini et al		
	AB	US- 2003/0064381	04/03/2003	Bonini et al		
	AC	US- 6,468,756	10/22/2002	Bonini et al		
	AD	US- 6,221,660	04/24/2001	Bonini et al		
	AE	US- 5,932,445	08/03/1999			
	AF	US 2003/0180813	09/25/2003			
	AG	US-2003/0139590	07/24/2003			

		FOREIGN PA	ATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	EP 1 092 727 A2	01/18/2001	Pfizer Limited et al		
	ВВ	WO 01/32864 A1	02/10/2001	Merck Patent GMBH et al		
	вс	WO 01/87929 A2	11/22/2001	Bayer Aktiengesellshaft et al.		
	BD	WO 00/31258 A2	06/02/2000	Arena Pharmaceuticals Inc., et al		
	BE	WO 01/36473 A2	05/25/2001	Pharmacia & Upjohn Co.		
	BF	WO 00/50562	08/31/2000	Synaptic Corporation		
	BG	WO 01/42288 A2	06/14/2001	Incyte Genomics, Inc.		
	вн	WO 02/186548 A2 (W/ English Abstract)	02/28/2002	Japan Science and Technology Corporation		
	ВІ	WO 02/0244362 A1 (w./ English Abstract)	06/06/2002	Yamanouchi Pharmaceutical Co., Ltd.		
	BJ	EP 1338651	08/27/2003	Yamanouchi Pharmaceutical Co. Ltd.		
	вк					
	BL					
	ВМ					

Examiner Signature	Date Considered	\bigcap

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to

place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 Complete if Known

 Application Number
 09/875,076

 Filing Date
 June 6, 2001

 First Named Inventor
 Ruoping Chen

 Group Art Unit
 1646

 Examiner Name
 Prema Mertz

 Attorney Docket Number
 11.US9.DIV

(use as many sheets as necessary)

Sheet 2 of 2

Substitute for form 1449A/PTO

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	CA	Bentley, "Genomic sequence information should be release immediately and freely to the public," The Sanger Institute: Human Genome Project, Policy Forum, Science (1996) 274:533-534.	
	СВ	The Sanger Institute: Data Release Policy, www.sanger.ac.uk, May 24, 2002.	
	СС	Genbank Acc. #AL035423, update version of February 12, 1999.	
	CD	Genbank Acc #AL035423, update version of February 24, 1999.	
	CE	Genbank Acc. #AL035423, update version of February 27, 1999.	
	CF	Genbank Acc. #AL035423, update version of April 21, 1999	
	CG	Genbank Acc. #AL035423, update version of November 23, 1999.	
	СН	Sequence Revision History for Genbank Acc. #AL035423.	
	CI	·	
	C1		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.